UNRESECTABLE

作品数：222被引量：1089H指数：18
导出分析报告
相关领域：医药卫生农业科学更多>>
相关作者：丁昂刘斌陆建贾中芝朱海东更多>>
相关机构：常州市第二人民医院南通市肿瘤医院北京肿瘤医院东南大学更多>>
相关期刊：更多>>
相关基金：国家自然科学基金国家高技术研究发展计划广东省自然科学基金安徽省自然科学基金更多>>
-
在结果中检索

检索结果分析

结果分析中...
共 条 记 录，以下是1-10
全选清除导出
参考文献引证文献引用追踪
视图：
排序：
Overall survival with frontline vs subsequent anti-epidermal growth factor receptor therapies in unresectable,RAS/BRAF wild-type,leftsided metastatic colorectal cancer
《World Journal of Clinical Oncology》2025年第3期57-67,共11页Nussara Pakvisal Richard M Goldberg Chirawadee Sathitruangsak Witthaya Silaphong Satawat Faengmon Nattaya Teeyapun Chinachote Teerapakpinyo Suebpong Tanasanvimon 
BACKGROUND The combination of anti-epidermal growth factor receptor(EGFR)therapy and chemotherapy is currently a preferred first-line treatment for patients with unre-sectable,RAS and BRAF wild-type,left-sided metasta...
关键词：Metastatic colorectal cancer Anti-epidermal growth factor receptor FRONTLINE Subsequent line RAS wild-type metastatic colorectal cancer BRAF wild-type metastatic colorectal cancer Left-sided metastatic colorectal cancer Overall survival 
Treatment of intermediate-to-advanced unresectable hepatocellular carcinoma is shifting toward a multidisciplinary strategy that includes multiple modalities as needed
《World Journal of Gastroenterology》2025年第10期151-158,共8页Ken Sato 
In the recent issue of the World Journal of Gastroenterology,Han et al compared the efficacy of and adverse reactions to bevacizumab versus lenvatinib as molecularly targeted agents in combination with interventional ...
关键词：Hepatocellular carcinoma Molecularly targeted therapy IMMUNOTHERAPY Interventional therapy Radiation therapy 
Addition of SHR-1701 to first-line capecitabine and oxaliplatin(XELOX) plus bevacizumab for unresectable metastaticcolorectal cancer
《Signal Transduction and Targeted Therapy》2025年第1期340-349,共10页Miao-Zhen Qiu Yuxian Bai Jufeng Wang Kangsheng Gu Mudan Yang Yifu He Cheng Yi Yongdong Jin Bo Liu Feng Wang Yu-kun Chen Wei Dai Yingyi Jiang Chuanpei Huang Rui-Hua Xu Hui-Yan Luo 
supported by Jiangsu Hengrui Pharmaceuticals and the following grants:the National Natural Science Foundation of China(NSFC:82321003,82173128,82073377,81930065);the Natural Science Foundation of Guangdong(2021A1515012439);Guangdong Basic and Applied Basic Research Foundation(2024B1515020120);the CAMS Innovation Fund for Medical Sciences(CIFMS:2019-I2M-5-036);Additional funding was provided by the Cancer Innovative Research Program of Sun Yat-sen University Cancer Center(CIRP-SYSUCC-0004).
This phase 2/3 trial (NCT04856787) assessed the efficacy and safety of SHR-1701, a bifunctional protein targeting PD-L1 and TGF-β,in combination with BP102 (a bevacizumab biosimilar) and XELOX (capecitabine plus oxal...
关键词：BEVACIZUMAB colorectal SHR 
Anlotinib plus chemotherapy as afirst-line treatment for gastrointestinal cancer patients with unresectable liver metastases:a multicohort,multicenter,exploratory trial
《Signal Transduction and Targeted Therapy》2025年第1期303-313,共11页Jun-Wei Wu Chen-Fei Zhou Zheng-Xiang Han Huan Zhang Jun Yan Jun Chen Chun-Bin Wang Zhi-Quan Qin Yong Mao Xin-Yu Tang Liang-Jun Zhu Xiao-Wei Wei Dong-Hai Cui Xiu-Li Yang Min Shi Li-Qin Zhao Jin-Ling Jiang Wei-You Zhu Hong-Mei Wang Chun Wang Ling-Jun Zhu Jun Zhang 
supported by the National Natural Science Foundation of China(82273126 and 82273407);the Collaborative Innovation Cluster Project of the Shanghai Municipal Health Commission(grant number,2020CXJQ03);the Innovative research teams of high-level local universities in Shanghai.The authors thank all patients,their families,investigators,and research staffs for participating in this trial.
This multicohort phase II trial(ALTER-G-001;NCT05262335)aimed to assess the efficacy offirst-line anlotinib plus chemotherapy for gastrointestinal(GI)cancer patients with unresectable liver metastases.Eligible patient...
关键词：patients METASTASES GASTROINTESTINAL 
Alternating modified CAPOX/CAPIRI plus bevacizumab in untreated unresectable metastatic colorectal cancer:a phase 2 trial
《Signal Transduction and Targeted Therapy》2025年第1期321-327,共7页Sheng Li Xiaoyou Li Hanfeng Xu Jiayuan Huang Jingni Zhu Ying Peng Jun Bao Liangjun Zhu 
supported by Beijing Science and Technology Innovation Medical Development Foundation(grant no.KC2021-JX-0186-106).
Previous studies showed encouraging efficacy of alternating FOLFOX/FOLFIRI for metastatic colorectal cancer(mCRC).This phase 2 trial(NCT04324476)aimed to evaluate efficacy and safety of alternating modified CAPOX(cape...
关键词：BEVACIZUMAB UNTREATED COLORECTAL 
Efficacy and safety of transhepatic arterial chemoembolization with drug-loaded microspheres in unresectable primary liver cancer
《World Journal of Gastrointestinal Oncology》2024年第12期4728-4737,共10页Jun Deng Yan-Hong Mi Le Xie Xiong-Xing Sun Dan-Hong Liu Hua-Jun Long Li-Yong He Da-Hua Wu Hong-Cai Shang 
Supported by Scientific Research project of Hunan Provincial Health Commission,No.B202303077689;Hunan Natural Science Foundation Project,No.2023JJ40397.
BACKGROUND Transhepatic arterial chemoembolization(TACE),as a local treatment,has been widely used in the treatment of unresectable liver cancer.The introduction of drug carrier microspheres has brought new hope for t...
关键词：Transhepatic arterial chemoembolization Drug-loaded microspheres Unresectable primary liver cancer Metaanalysis 
Combinations of lenvatinib and immune checkpoint inhibitors plus transarterial chemoembolization,is it the prime time for unresectable hepatocellular carcinoma?
《World Journal of Gastrointestinal Oncology》2024年第12期4753-4756,共4页Natalia Centrone Pedro Luiz Serrano Uson Junior 
Hepatocellular carcinoma(HCC)is a lethal disease and unfortunately,most patients will be diagnosed with unresectable/advanced stages and the overall prognosis is poor.For patients with initially unresectable HCC(uHCC)...
关键词：Hepatocellular carcinoma Liver cancer Lenvatinib Immunotherapy Checkpoint inhibitors 
Exciting progress in targeted therapy innovation for unresectable stage Ⅲ EGFR-mutated NSCLC:the phase Ⅲ LAURA study
《Cancer Communications》2024年第12期1381-1384,共4页Ziyan Tong Ning Zhu Hong Shen Ying Yuan 
Key Research and Development Program of Zhejiang Province,Grant/Award Number:2021C03125;National Natural Science Foundation of China,Grant/Award Number:82373415。
Based on the PACIFIC trial(NCT02125461),the standard treatment for unresectable stage Ⅲ non-small cell lung cancer(NSCLC)is chemoradiotherapy(CRT)followed by durvalumab consolidation[1].However,a subsequent post-hoc ...
关键词：NSCLC LUNG TARGETED 
Comparison of drug-eluting bead transarterial chemoembolization combined with apatinib versus drugeluting bead transarterial chemoembolization for the treatment of unresectable hepatocellular carcinoma:a randomized,prospective,multicenter phase III trial
《Signal Transduction and Targeted Therapy》2024年第12期5684-5692,共9页Xuhua Duan Hao Li Donglin Kuang Pengfei Chen Mengfan Zhang Tengfei Li Dechao Jiao Yanliang Li Xiang He Cheng Xing Haibo Wang Yaoxian Liu Limin Xie Shixi Zhang Qiang Zhang Peixin Zhu Yongchuang Chang Jichen Xie Jianzhuang Ren Xinwei Han 
supported by the National Natural Science Foundation of China(No.U2004119);Major Science and Technology Projects in Henan Province(No.221100310100);the Henan Province Medical Science and Technology Public Relations Plan Province Department joint construction project(No.SBGJ202102100).
This randomized,prospective,multicenter(12 centers in China)phase III trial(Chinese Clinical Trial Registry#ChiCTR2000041170)compared drug-eluting bead transarterial chemoembolization(DEB-TACE)combined with apatinib a...
关键词：elevated RANDOMIZED markedly 
Lenvatinib,sintilimab combined interventional treatment vs bevacizumab,sintilimab combined interventional treatment for intermediate-advanced unresectable hepatocellular carcinoma被引量：2
《World Journal of Gastroenterology》2024年第43期4620-4635,共16页Ru-Yu Han Lei-Juan Gan Meng-Ran Lang Shao-Hua Ren Dong-Ming Liu Guang-Tao Li Ya-Yue Liu Xin-Di Tian Kang-Wei Zhu Li-Yu Sun Lu Chen Tian-Qiang Song 
Supported by The National Natural Science Foundation of China,No.82173317;The Scientific Research Projects of Tianjin Education Commission,No.2022KJ227;The Doctoral Start-up Fund of Tianjin Medical University Cancer Institute&Hospital,No.B2208.
BACKGROUND Bevacizumab and sintilimab combined interventional treatment(BeSiIT)and L envatinib and sintilimab combined interventional treatment(LeSiIT)are two commonly used therapeutic regimens for intermediate-advanc...
关键词：Hepatocellular carcinoma Molecular targeted therapy IMMUNOTHERAPY Interventional treatment Propensity score matching 
全选清除导出
共23页<12345678910>
检索报告 对象比较 聚类工具 使用帮助 返回顶部